The T341C (Ile114Thr) polymorphism of N-acetyltransferase 2 yields slow acetylator phenotype by enhanced protein degradation

Pharmacogenetics

Volumn 14, Issue 11, 2004, Pages 717-723

  Zang, Yu ^a   Zhao, Shuang ^a   Doll, Mark A ^a   States, J Christopher ^a   Hein, David W ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

N acetyltransferase 2; NAT2; acetylator genotype; Protein degradation; Single nucleotide polymorphism; Slow acetylator phenotype; SNP

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; COMPLEMENTARY DNA; ISOLEUCINE; MESSENGER RNA; PROTEIN NAT2; RECOMBINANT ENZYME; THREONINE; UNCLASSIFIED DRUG; NAT2 PROTEIN, HUMAN; PRIMER DNA;

ACETYLATOR PHENOTYPE; ALLELE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BIOTRANSFORMATION; CANCER SUSCEPTIBILITY; CATALYSIS; CONTROLLED STUDY; DNA DETERMINATION; DRUG CLEARANCE; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME POLYMORPHISM; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REGULATORY MECHANISM; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; THERMOSTABILITY; TRANSCRIPTION REGULATION; ACETYLATION; ANIMAL; CELL STRAIN COS1; GENETICS; HYDROLYSIS; METABOLISM; NUCLEOTIDE SEQUENCE; PHENOTYPE; SITE DIRECTED MUTAGENESIS; WESTERN BLOTTING;

ACETYLATION; ANIMALS; ARYLAMINE N-ACETYLTRANSFERASE; BASE SEQUENCE; BLOTTING, WESTERN; COS CELLS; DNA PRIMERS; HUMANS; HYDROLYSIS; ISOLEUCINE; MUTAGENESIS, SITE-DIRECTED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, MESSENGER; THREONINE;

EID: 9244240756     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200411000-00002     Document Type: Article

References (29)

1. Weber WW, Hein DW. N-acetylation pharmacogenetics. Pharmacol Rev 1985; 37:25-79.
2. Ghoshal A, Davis CD, Schut HA, Snyderwine EG. Possible mechanisms for PhlP-DNA adduct formation in the mammary gland of female Sprague-Dawley rats. Carcinogenesis 1995; 16:2725-2731.
3. Hein DW, Doll MA, Rustan TD, Ferguson RJ. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. Cancer Res 1995; 55:3531-3536.
4. Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000; 9:29-42.
5. Slum M, Demierre A, Grant DM, Heim M, Meyer UA. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci U S A 1991; 88:5237-5241.
6. Vatsis KP, Martell KJ, Weber WW. Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proc Natl Acad Sci USA 1991; 88:6333-6337.
7. Hickman D, Risch A, Camilleri JP, Sim E. Genotyping human polymorphic arylamine N-acetyltransferase: identification of new slow allotypic variants. Pharmacogenetics 1992; 2:217-226.
8. Abe M, Deguchi T, Suzuki T. The structure and characteristics of a fourth allele of polymorphic N-acetyltransferase gene found in the Japanese population. Biochem Biophys Res Commun 1993; 191:811-816.
9. Left MA, Fretland AJ, Doll MA, Hein DW. Novel human N-acetyltransferase 2 alleles that differ in mechanism for slow acetylator phenotype. J Biol Chem 1999; 274:34519-34522.
10. Fretland AJ, Leff MA, Doll MA, Hein DW. Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms. Pharmacogenetics 2001; 11:207-215.
11. Grant DM, Blum M, Beer M, Meyer UA. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol 1991; 39:184-191.
12. Zhu Y, Doll MA, Hem DW. Functional genomics of C190T single nucleotide polymorphism in human N-acetyltransferase 2. Biol Chem 2002; 383:983-987.
13. Cartwright RA, Glashan RW, Rogers HJ, Ahmad RA, Barham-Hall D, Higgins E, et al. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancer 1982; 2:842-845.
14. Marcus PM, Hayes RB, Vineis P, Garcia-Closas M, Caporaso NE, Autrup H, et al. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction. Cancer Epidemiol Biomarkers Prev 2000; 9:461-467.
15. Risch A, Wallace DM, Bathers S, Sim E. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet 1995; 4:231-236.
16. Hein DW, Leff MA, Ishibe N, Sinha R, Frazier HA, Doll MA, et al. Association of prostate cancer with rapid N-acetyltransferase 1 (NAT1*10) in combination with slow N-acetyltransferase 2 acetylator genotypes in a pilot case-control study. Environ Mol Mutagen 2002; 40:161-167.
17. Ambrosone CB, Freudenheim JL, Graham S, Marshall JR, Vena JE, Brasure JR, et al. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. JAMA 1996; 276:1494-1501.
18. van der Hel OL, Peelers PHM, Hein DW, Doll MA, Brobbee DE, Kromhout D, et al. NAT2 slow acetylation and GSTM1 null genotypes may increase postmenopausal breast cancer risk in long-term smoking women. Pharmacogenetics 2003; 13:399-407.
19. Hickman D, Palamanda JR, Unadkat JD, Sim E. Enzyme kinetic properties of human recombinant arylamine N-acetyltransferase 2 allotypic variants expressed in Escherichia coli. Biochem Pharmacol 1995; 50:697-703.
20. Grant DM, Hughes NC, Janezic SA, Goodfellow GH, Chen HJ, Gaedigk A, et al. Human acetyltransferase polymorphisms. Mutat Res 1997; 376:61-70.
21. Grant DM, Morike K, Eichelbaum M, Meyer UA. Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J Clin Invest 1990; 85:968-972.
22. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 1994; 79:13-21.
23. Tai HL, Fessing MY, Bonten EJ, Yanishevsky Y, d'Azzo A, Krynetski EY, et al. Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C. Pharmacogenetics 1999; 9:641-650.
24. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998; 393:229-234.
25. Siegel D, Anwar A, Winski SL, Kepa JK, Zolman KL, Ross D. Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:Quinone oxidoreductase 1. Mol Pharmacol 2001; 59:263-268.
26. Hein DW. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res 2002; 506-507:65-77.
27. Dupret JM, Goodfellow GH, Janezic SA, Grant DM. Structure-function studies of human arylamine N-acetyltransferases NAT1 and NAT2. Functional analysis of recombinant NAT1/NAT2 chimeras expressed in Escherichia coli. J Biol Chem 1994; 269:26830-26835.
28. Hein DW, Rustan TD, Ferguson RJ, Doll MA, Gray K. Metabolic activation of aromatic and heterocyclic N-hydroxyarylamines by wild-type and mutant recombinant human NAT1 and NAT2 acetyltransferases. Arch Toxicol 1994; 68:129-133.
29. Butcher NJ, Arulpragasam A, Minchin RF. Proteasomal degradation of N-acetyltransferase1 is prevented by acetylation of the active site cysteine. J Biol Chem 2004; 279:22131-22137.